deltatrials
Terminated PHASE4 INTERVENTIONAL 2-arm NCT01443923

Boceprevir Drug Combination for Hepatitis C Treatment in People With and Without HIV

An Open Label, On-Treatment Trial to Assess the Effect of HIV-1 Coinfection on Therapeutic Responses Using Boceprevir, Peg-Interferon-alfa-2b and Ribavirin in HCV Genotype 1, IFN Treatment-Naive Subjects With or Without HIV-1

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Conditions HIV/AIDS Hepatitis
Interventions Boceprevir Peg-Interferon-alfa 2B Ribavirin
Updated 7 times since 2017 Last updated: Jul 9, 2015 Started: Sep 30, 2011 Primary completion: Sep 30, 2013 Completion: Sep 30, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Unable to complete enrollment due to newly approved treatment options.

Other terminated trials from National Institute of Allergy and Infectious Diseases (NIAID)

See all terminations from National Institute of Allergy and Infectious Diseases (NIAID)

Other HIV/AIDS trials with similar outcome

Browse all HIV/AIDS trials

Listed as NCT01443923, this PHASE4 trial focuses on HIV/AIDS and Hepatitis and remains terminated or withdrawn. Sponsored by National Institute of Allergy and Infectious Diseases (NIAID), it has been updated 7 times since 2011, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotTerminated~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 9 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE4

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE4

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE4

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE4

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE4

  2. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE4

    First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations